Literature DB >> 27465835

The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.

Isidro Machado1, Samuel Navarro2, Piero Picci3, Antonio Llombart-Bosch2.   

Abstract

SATB2 is commonly expressed in osteosarcomas. Although apparently being a valuable diagnostic marker for differentiating between small cell osteosarcoma (SCO) and other small round cell tumors of bone, for instance Ewing sarcoma family of tumors (ESFT), it has not been tested in a large series of ESFT and chondrosarcomas so far. We studied the immunohistochemical expression of SATB2 in 42 osteosarcomas, 31 chondrosarcomas, and 371 genetically confirmed ESFT. SATB2 positivity was detected in 90.4% of osteosarcomas, 87.5% of SCO, 91.3% of osteoblastic osteosarcomas, and in all chondroblastic and parosteal osteosarcomas. The osteoblastic and SCO subtypes expressed SATB2 more intensely than other histological types. SATB2 was expressed in 46.6% of chondrosarcomas, and in 1.3% of ESFT. Sensitivity and specificity of SATB2 immunoexpression were 90.4% and 95.3%, respectively. The positive and negative predictive values in osteosarcoma diagnosis were 66.6% and 98.9%, respectively. In chondrosarcoma, SATB2 immunoexpression was more frequent and intense in high-grade chondrosarcoma (Grade III) and uncommon in chondrosarcoma grade I. SATB2 positivity was detected in 55.6% of chondrosarcomas grade II. SATB2 apparently cannot distinguish between chondroblastic osteosarcoma and high-grade chondrosarcoma. Nevertheless, SATB2 is frequently expressed in osteogenic tumors, but is rarely positive in ESFT, and with the support of CD99 expression and specific molecular studies, it is very useful for distinguishing between these two lesions. Although SATB2 immunoexpression helps to distinguish osteosarcoma from their mimickers, the identification of malignant osteoid matrix formation and the integration of clinical and radiological data remain the corner stone of osteosarcoma diagnosis and as yet no antibody has equalled the diagnostic value of this important morphologic hallmark.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Chondrosarcoma; Ewing sarcoma; Osteosarcoma; SATB2 immunohistochemistry

Mesh:

Substances:

Year:  2016        PMID: 27465835     DOI: 10.1016/j.prp.2016.06.012

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  12 in total

1.  Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation.

Authors:  Julia N Cheng; Jennifer B Frye; Susan A Whitman; Janet L Funk
Journal:  Clin Exp Metastasis       Date:  2019-12-20       Impact factor: 5.150

Review 2.  [New in the current WHO classification (2020) for soft tissue sarcomas].

Authors:  Eva Wardelmann; Wolfgang Hartmann
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

Review 3.  [Ewing sarcomas and Ewing-like sarcomas : New aspects].

Authors:  K Specht; W Hartmann
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

Review 4.  Biomarkers of chondrosarcoma.

Authors:  Wonju Jeong; Ha-Jeong Kim
Journal:  J Clin Pathol       Date:  2018-03-28       Impact factor: 3.411

Review 5.  Avenues of research in dietary interventions to target tumor metabolism in osteosarcoma.

Authors:  Taiana Campos Leite; Rebecca Jean Watters; Kurt Richard Weiss; Giuseppe Intini
Journal:  J Transl Med       Date:  2021-10-29       Impact factor: 5.531

6.  The behavioural phenotype of SATB2-associated syndrome: a within-group and cross-syndrome analysis.

Authors:  Stacey Bissell; Chris Oliver; Joanna Moss; Mary Heald; Jane Waite; Hayley Crawford; Vishakha Kothari; Lauren Rumbellow; Grace Walters; Caroline Richards
Journal:  J Neurodev Disord       Date:  2022-03-29       Impact factor: 4.025

Review 7.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

8.  Clinical, histopathologic, subtype, and immunohistochemical analysis of jaw phosphaturic mesenchymal tumors.

Authors:  Dongmei Li; Ran Zhu; Lian Zhou; Dingrong Zhong
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

9.  Cytokeratin-Positive Osteosarcoma Simulating Sarcomatoid Metastatic Carcinoma.

Authors:  Hamza Murtaza; Abdul Rehman Arain; Afshin Anoushiravani; Sean Thadani; Gustavo de la Roza; Rana Naous; Timothy A Damron
Journal:  Case Rep Orthop       Date:  2020-02-04

10.  SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw.

Authors:  Adepitan A Owosho; Adeola M Ladeji; Olufunlola M Adesina; Kehinde E Adebiyi; Mofoluwaso A Olajide; Toluwaniyin Okunade; Jacob Palmer; Temitope Kehinde; Jeffrey A Vos; Grayson Cole; Kurt F Summersgill
Journal:  Dent J (Basel)       Date:  2021-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.